Open Access
ARTICLE
Overexpression of lnc-ERP44-3:6 Causes Cell Death and Sensitivity to Cisplatin in Breast Cancer Cell Lines
Elda A. Flores-Contreras1, Everardo González-González2,3, Ana I. Zarazúa-Niño1, Elsa N. Garza-Treviño1, Natalia Martínez-Acuña1, Viviana C. Zomosa-Signoret4, Román Vidaltamayo4, Gerardo E. Muñoz-Maldonado5, Raquel Garza-Guajardo6, Manuel de J. García-Solís7, Alejandro Abarca-Blanco3, Ana M. G. Rivas-Estilla1, Carlos Córdova-Fletes1,*
1 Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Nuevo León, 64460, Mexico
2 Centro de Biotecnología-FEMSA, Tecnológico de Monterrey, Nuevo León, 64849, Mexico
3 Delee Corp, Mountain View, CA 94041, USA
4 Department of Basic Science, School of Medicine, Universidad de Monterrey, Nuevo León, 66238, Mexico
5 Department of General Surgery, Hospital Universitario, Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Nuevo León, 66460, Mexico
6 Department of Pathology and Cytopathology, Facultad de Medicina, Dr. José Eleuterio Gonzáles, Universidad Atónoma de Nuevo León, Nuevo León, 66460, Mexico
7 Clínica de Mama, Hospital Metropolitano, Dr. Bernardo Sepúlveda, Secretaría de Salud, Nuevo León, 66480, Mexico
* Corresponding Author: Carlos Córdova-Fletes. Email:
Oncologie 2021, 23(3), 373-392. https://doi.org/10.32604/oncologie.2021.017786
Received 06 June 2021; Accepted 14 August 2021; Issue published 26 September 2021
Abstract
Breast cancer (BC) is one of the leading causes of death in women worldwide. A major challenge in BC is chemoresistance, which is often modulated by epigenetic regulators such as long non-coding RNAs (lncRNAs). Because these regulator lncRNAs may play diverse roles, determining their specific pathways and/or functions is crucial to identify possible biomarkers and/or therapeutic targets for BC. In this study, we used gene expression microarrays in order to identify lncRNAs related to the BC biology. We found, among six differentially expressed (DE) lncRNAs, that the expression of
lnc-ERP44-3:6 was consistently down-regulated in all breast tumor tissues compared to normal adjacent tissues of BC patients from northeastern Mexico. Since the role of
lnc-ERP44-3:6 remains unknown in BC, we induced its transient overexpression in three different BC cell lines (i.e., MCF10A, MCF-7, and HCC1395) by transfection in order to elucidate its potential downstream effects. Remarkably, our results showed a significant increase in cell death and chemosensitivity to cisplatin at 48 h post-transfection (
p < 0.01). In addition, we observed that
GAPDH and
FAS were up-regulated following the overexpression of
lnc-ERP44-3:6. As
GAPDH and
FAS promote apoptosis in cancer, our findings suggest that the
lnc-ERP44-3:6 overexpression induces cell death possibly via up-regulation of one or both genes in BC cell lines. To the best of our knowledge, this is the first study evaluating the overexpression of
lnc-ERP44-3:6 and providing insights about its role in BC cells, which suggests that this lncRNA may be an interesting candidate as a potential therapeutic target for BC in our population. However, further studies would be needed to clarify the mechanisms by which an overexpression of
lnc-ERP44-3:6 causes both cell death and chemosensitivity to cisplatin.
Keywords
Cite This Article
APA Style
Flores-Contreras, E.A., González-González, E., Zarazúa-Niño, A.I., Garza-Treviño, E.N., Martínez-Acuña, N. et al. (2021). Overexpression of <i>lnc-erp44-3:6</i> causes cell death and sensitivity to cisplatin in breast cancer cell lines. Oncologie, 23(3), 373-392. https://doi.org/10.32604/oncologie.2021.017786
Vancouver Style
Flores-Contreras EA, González-González E, Zarazúa-Niño AI, Garza-Treviño EN, Martínez-Acuña N, Zomosa-Signoret VC, et al. Overexpression of <i>lnc-erp44-3:6</i> causes cell death and sensitivity to cisplatin in breast cancer cell lines. Oncologie . 2021;23(3):373-392 https://doi.org/10.32604/oncologie.2021.017786
IEEE Style
E.A. Flores-Contreras et al., "Overexpression of <i>lnc-ERP44-3:6</i> Causes Cell Death and Sensitivity to Cisplatin in Breast Cancer Cell Lines," Oncologie , vol. 23, no. 3, pp. 373-392. 2021. https://doi.org/10.32604/oncologie.2021.017786